From the Department of Plastic, Reconstructive and Aesthetic Surgery, ISAR Klinikum.
Clinic for Plastic, Reconstructive and Hand Surgery, Klinikum Rechts der Isar, Technische Universität München, Munich, Germany.
Ann Plast Surg. 2024 Sep 1;93(3):283-289. doi: 10.1097/SAP.0000000000004020. Epub 2024 Jul 9.
Effective postoperative pain management is essential for patient satisfaction and an uneventful postoperative course, particularly in body contouring procedures. Systemic analgesic regimens can be supported by regional procedures, such as the transverse abdominis plane (TAP) block, but these have a limited duration of action. In contrast, thoracic epidural analgesia offers the possibility of a longer-lasting, individualized regional anesthesia administered by a patient-controlled analgesia pump.
The aim of this study was to investigate the effects of a patient-controlled epidural analgesia to better classify the clinical value of this procedure in abdominoplasties.
This work reviewed the digital medical charts of patients who underwent selective abdominoplasty without combined surgical procedures between September 2018 and August 2022. Evaluated data comprise the postoperative analgesia regimen, including on-demand medication, mobilization time, inpatient length of stay, and clinical outcome. The patients were grouped by the presence of a thoracic epidural catheter. This catheter was placed before anesthetic induction and a saturation dose was preoperatively applied. Postoperative PCEA patients received a basal rate and could independently administer boluses. Basal rate was individually adjusted during daily additional pain visits.
The study cohort included 112 patients. Significant differences in the demand for supportive nonepidural opiate medication were shown between the patient-controlled epidural analgesia (PCEA) group (n = 57) and the non-PCEA group (n = 55), depending on the time after surgery. PCEA patients demanded less medication during the early postoperative days (POD 0: PCEA 0.13 (±0.99) mg vs non-PCEA 2.59 (±4.55) mg, P = 0.001; POD 1: PCEA 0.79 mg (±3.06) vs non-PCEA 2.73 (±3.98) mg, P = 0.005), but they required more during the later postoperative phase (POD 3: PCEA 2.76 (±5.60) mg vs non-PCEA 0.61 (±2.01) mg, P = 0.008; POD 4: PCEA 1.64 (±3.82) mg vs non-PCEA 0.07 (±2.01) mg, P = 0.003). In addition, PCEA patients achieved full mobilization later (PCEA 2.67 (±0.82) days vs non-PCEA 1.78 (±1.09) days, P = 0.001) and were discharged later (PCEA 4.84 (±1.23) days vs non-PCEA 4.31 (±1.37) days, P = 0.005).
Because the postoperative benefits of PCEA are limited to potent analgesia immediately after abdominoplasty, less cumbersome, time-limited regional anesthesia procedures (such as TAP block) appear not only adequate but also more effective.
有效的术后疼痛管理对于患者满意度和顺利的术后过程至关重要,尤其是在身体塑形手术中。全身镇痛方案可以通过区域程序(如腹横肌平面(TAP)阻滞)得到支持,但这些方案的作用持续时间有限。相比之下,胸椎硬膜外镇痛提供了一种可能性,可以通过患者自控镇痛泵进行更持久、个体化的区域麻醉。
本研究旨在探讨患者自控硬膜外镇痛的效果,以更好地评估该程序在腹部整形术中的临床价值。
本研究回顾性分析了 2018 年 9 月至 2022 年 8 月期间接受选择性腹部整形术且未合并手术的患者的数字病历。评估数据包括术后镇痛方案,包括按需药物、活动时间、住院时间和临床结果。根据是否存在胸椎硬膜外导管将患者分为两组。该导管在麻醉诱导前放置,并在术前给予饱和剂量。术后行 PCEA 的患者接受基础输注,并可自行给予推注。基础输注率在每天的额外疼痛就诊期间进行个体化调整。
本研究队列包括 112 名患者。结果显示,根据手术时间的不同,患者自控硬膜外镇痛(PCEA)组(n = 57)和非 PCEA 组(n = 55)在对非硬膜外阿片类药物的需求方面存在显著差异。在术后早期(术后第 0 天:PCEA 0.13(±0.99)mg 比非 PCEA 2.59(±4.55)mg,P = 0.001;术后第 1 天:PCEA 0.79 mg(±3.06)比非 PCEA 2.73(±3.98)mg,P = 0.005),PCEA 患者对药物的需求较低,但在术后晚期(术后第 3 天:PCEA 2.76(±5.60)mg 比非 PCEA 0.61(±2.01)mg,P = 0.008;术后第 4 天:PCEA 1.64(±3.82)mg 比非 PCEA 0.07(±2.01)mg,P = 0.003),PCEA 患者对药物的需求较高。此外,PCEA 患者的完全活动时间较晚(PCEA 2.67(±0.82)天比非 PCEA 1.78(±1.09)天,P = 0.001),出院时间也较晚(PCEA 4.84(±1.23)天比非 PCEA 4.31(±1.37)天,P = 0.005)。
由于 PCEA 的术后益处仅限于腹部整形术后即刻强效镇痛,因此不太繁琐、作用时间有限的区域麻醉程序(如 TAP 阻滞)不仅足够有效,而且更有效。